Homocysteine and Reclassification of Cardiovascular Disease Risk
- 23 August 2011
- journal article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 58 (10), 1025-1033
- https://doi.org/10.1016/j.jacc.2011.05.028
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Meta-Analysis of Folic Acid Supplementation Trials on Risk of Cardiovascular Disease and Risk Interaction With Baseline Homocysteine LevelsThe American Journal of Cardiology, 2010
- The homocysteine controversyJournal of Inherited Metabolic Disease, 2010
- Coronary Artery Calcium Score and Risk Classification for Coronary Heart Disease PredictionJAMA, 2010
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2009
- Predictive Value of Brachial Flow-Mediated Dilation for Incident Cardiovascular Events in a Population-Based StudyCirculation, 2009
- Criteria for Evaluation of Novel Markers of Cardiovascular RiskCirculation, 2009
- C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart StudyCirculation: Cardiovascular Quality and Outcomes, 2008
- Current and Future Directions of Cardiovascular Risk PredictionThe American Journal of Cardiology, 2006
- Prospective Study of Serum Homocysteine and Risk of Ischemic Stroke Among Patients With Preexisting Coronary Heart DiseaseStroke, 2003